Previous 10 | Next 10 |
NCD Academy Launches New Health Equity and Social Determinants of Health Course PR Newswire Innovative online education platform helping global healthcare professionals address non-communicable diseases PITTSBURGH and WASHINGTON , April 6, 2023 /PRNew...
2023-04-05 10:23:00 ET Dividend stocks can give you recurring cash flow to help pay bills or save for the future. The downside is that most of them pay every three months. However, you can accelerate the rate of your dividend payments by investing in multiple stocks that pay dividends at di...
2023-03-31 16:09:59 ET Viatris ( NASDAQ: VTRS ) is asking for new offers for its European consumer-health assets after initial bids failed to meet its expectations. The company has asked potential buyers to resubmit their offers, according to a Bloomberg report, which cited ...
2023-03-31 11:11:44 ET A panel of the European Medicines Agency (EMA) said that Viatris ( NASDAQ: VTRS ) withdrew an application for a generic HIV therapy Raltegravir Viatris on Feb. 22. Raltegravir Viatris was developed as an antiviral drug to treat human immun...
2023-03-31 08:00:00 ET Viatris (NASDAQ: VTRS) and Apple (NASDAQ: AAPL) are two dividend-paying stocks that don't have much in common, which can make them a bit difficult to compare as investments. Whereas Viatris makes generic medicines like Lipitor, Apple makes its own bran...
Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025 PDUFA Date of September 28, 2023 Set for Nyxol ® in its First Indication, Reversal of Pharmacologically-induced Mydr...
2023-03-30 05:13:16 ET The United Nations-backed Medicines Patent Pool (MPP) signed agreements with Aurobindo, Cipla and Viatris ( NASDAQ: VTRS ) to produce generic versions of ViiV Healthcare's long-acting HIV prevention medicine. ViiV — which is majority o...
2023-03-26 18:00:00 ET Summary To say Viatris has been a sore disappointment since its spin-off, would be a massive understatement. The company came into its listing on very low valuations and had to do very little right to deliver average returns. Instead the stock is near lo...
2023-03-26 08:45:00 ET Healthcare spinoffs aren't normally seen as companies with strong growth potential. More likely than not, spinoffs stem from a division of a company that, while possibly profitable, is seeing slower growth. Embecta (NASDAQ: EMBC.V) , Viatris (NASDAQ:...
2023-03-21 09:32:47 ET Viatris (NASDAQ: VTRS) makes both generic and branded drugs and its stock looks like a potential steal of a deal at the moment. It trades at less than 6 times its earnings, and it pays a dividend that today yields just over 5%. But when a stock is so heavi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...